Bone News and Research

RSS

Immune cells from healthy individuals effectively kill cancer cells

Immune cells from healthy individuals can be the new immune cure for cancer. This treatment can kill cancer cells without destroying neighbouring cells. The hope is to eradicate cancer for ever.

3 Feb 2012

$Heart failure associated with 30% increase in major fractures$

Heart failure associated with 30% increase in major fractures

Heart failure is associated with a 30 percent increase in major fractures and also identifies a high-risk population that may benefit from increased screening and treatment for osteoporosis, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

3 Feb 2012

$Heart burn drugs and hip fractures in postmenopausal women smokers: Study establishes link$

Heart burn drugs and hip fractures in postmenopausal women smokers: Study establishes link

A new study shows that postmenopausal women with a history of smoking who take heartburn drugs called proton pump inhibitors (PPIs) for two years or longer may be more likely to sustain a hip fracture. The risk rises with longer use say researchers. But the risk does disappear after women stop taking these drugs for two years. Further women who never smoked were not at increased risk for hip fracture even if they took PPIs regularly, the study showed. The new findings appear in the journal BMJ.

2 Feb 2012

Skin cells converted to brain cells without intermediate stem cell stage

Researchers from California have successfully converted mouse skin cells into cells which develop into the main components of the brain. The experiment, reported in Proceedings of the National Academy of Sciences, is notable because it skipped the middle “stem cell” stage in the process.

2 Feb 2012

Intra-arterial technique of stem cell transplantation may enhance functional recovery from TBI

Experiments in brain-injured rats show that stem cells injected via the carotid artery travel directly to the brain, where they greatly enhance functional recovery, reports a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

2 Feb 2012

Ligand announces results from melphalan Phase II study on multiple myeloma

Ligand Pharmaceuticals Incorporated announced that results from the Phase II study of its Captisol-enabled, propylene glycol-free (PG-free) Melphalan program were featured this evening in a poster presentation at the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) in San Diego.

2 Feb 2012

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Novartis announced today that following a priority review, the US Food and Drug Administration has approved an update to the Gleevec (imatinib mesylate) tablets label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial.

1 Feb 2012

Brief 10-minute massage helps reduce inflammation in muscle

Researchers at McMaster University have discovered a brief 10-minute massage helps reduce inflammation in muscle.

1 Feb 2012

Progenitor cells have potential to develop into RBCs

A study of the cells that respond to crises in the blood system has yielded a few surprises, redrawing the 'map' of how blood cells are made in the body.

1 Feb 2012

CartiHeal secures $5M in venture funding

CartiHeal (2009), Ltd, a privately held medical device company, focused on developing and bringing to market a proprietary, off-the-shelf, and cell-free cartilage regeneration technology, announced that it raised $5 million in venture funding from two US-Israeli venture capital firms, Accelmed and Access Medical Ventures. The financing will be used to prepare its first product launch early 2013 in Europe.

1 Feb 2012

Study finds sharp increase in BMP use for spinal fusion surgery

The use of bone morphogenetic protein (BMP) for spinal fusion surgery has risen sharply over the past decade, increasing costs with no evidence of improved outcomes, reports study in the February 1 issue of Spine.

1 Feb 2012

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors.

1 Feb 2012

Interim results from Allos Therapeutics' FOLOTYN and bexarotene Phase 1 combination study on CTCL

Allos Therapeutics, Inc. today reported interim results from the Company's ongoing Phase 1 combination study of FOLOTYN and bexarotene in patients with relapsed or refractory cutaneous T-cell lymphoma.

31 Jan 2012

FDA approves Genentech's Erivedge for treatment of BCC

Genentech, a member of the Roche Group, today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

31 Jan 2012

Hologic first quarter revenues increase 9.3% to $472.7 million

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its results for the first fiscal quarter ended December 24, 2011.

From Hologic, Inc. 31 Jan 2012

Custom Spine achieves ISO-13485 and receives CE Mark for all current products

In an effort to support global expansion plans, Custom Spine announced that it has achieved ISO-13485 and received CE Mark for all its current products sold in the U.S. This approval allows the Company to commercialize its products into the international market.

31 Jan 2012

Array second quarter revenue increases to $23.2 million

Array BioPharma Inc. today reported financial results for the second quarter of fiscal 2012.

31 Jan 2012

Psychosocial interventions can reduce cancer patients' pain severity

Researchers at Moffitt Cancer Center, who teamed with colleagues at five universities around the United States, analyzed past studies of cancer-related pain reduction and found that psychosocial interventions can have a beneficial effect on cancer patients' pain severity. They also found that certain psychosocial interventions provide better pain management and are effective in reducing the degree to which pain related to cancer and its treatment interferes with patients' lives.

31 Jan 2012

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

30 Jan 2012

Milk boosts brain and mental performance

Pouring at least one glass of milk each day could not only boost your intake of much-needed key nutrients, but it could also positively impact your brain and mental performance, according to a recent study in the International Dairy Journal.

30 Jan 2012